Serotonin 1B receptor agonists - Pipeline Insight, 2024

This “Serotonin 1B Receptor Agonists - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Serotonin 1B Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Serotonin 1B Receptor Agonists Understanding

Serotonin 1B Receptor Agonists: Overview

The 5-HT1B/1D receptor agonists, collectively known as triptans, are a major advance in the treatment of migraine. The beneficial effects of the triptans in patients with migraine are related to their multiple mechanisms of action at sites implicated in the pathophysiology of migraine. These mechanisms are mediated by 5-HT1B/1D receptors and include vasoconstriction of painfully dilated cerebral blood vessels, inhibition of the release of vasoactive neuropeptides by trigeminal nerves, and inhibition of nociceptive neurotransmission. The high affinity of the triptans for 5-HT1B/1D receptors and their favorable pharmacologic properties contribute to the beneficial effects of these drugs, including rapid onset of action, effective relief of headache and associated symptoms, and low incidence of adverse effects.

Increased understanding of the pathophysiology of migraine has led to the development of improved migraine treatments such as the 5-HT1B/1D receptor agonists, collectively known as triptans.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Serotonin 1B Receptor Agonists R&D. The therapies under development are focused on novel approaches for Serotonin 1B Receptor Agonists.

Serotonin 1B Receptor Agonists Emerging Drugs Chapters

This segment of the Serotonin 1B Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Serotonin 1B Receptor Agonists Emerging Drugs

STS-101: Satsuma Pharmaceuticals STS101 (dihydroergotamine mesylate (DHE) nasal powder) for the acute treatment of Serotonin 1B Receptor Agonists is Satsuma Pharmaceuticals’ lead product candidate. Both STS101 dosage strengths were well-tolerated in the EMERGE trial, with low adverse event rates and no serious adverse events reported.

It is currently in Phase III stage of development and is being developed by Satsuma Pharmaceuticals.

JM-010: Contera Pharma JM-010 is developed based on a poly-pharmacological approach to treat or prevent dyskinesia in Parkinson's disease. JM-010 combines the synergistic efficacy of two known drugs in a proprietary formulation. This will provide efficacy reducing involuntary movement without adverse effects. JM-010 has shown very convincing efficacy in preclinical and in Phase IIa cPoC. Based in the data JM-010 should provide a safe and efficacious treatment of dyskinesia in Parkinson's disease.

It is currently in Phase II stage of development and is being developed by Contera Pharma.

Serotonin 1B Receptor Agonists: Therapeutic Assessment

This segment of the report provides insights about the different Serotonin 1B Receptor Agonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Serotonin 1B Receptor Agonists

There are approx. 5+ key companies which are developing the Serotonin 1B Receptor Agonists. The companies which have their Serotonin 1B Receptor Agonists drug candidates in the most advanced stage, i.e. Phase III include, Satsuma Pharmaceuticals.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Serotonin 1B Receptor Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Serotonin 1B Receptor Agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Serotonin 1B Receptor Agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Serotonin 1B Receptor Agonists drugs.

Serotonin 1B Receptor Agonists Report Insights

• Serotonin 1B Receptor Agonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Serotonin 1B Receptor Agonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Serotonin 1B Receptor Agonists drugs?
• How many Serotonin 1B Receptor Agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Serotonin 1B Receptor Agonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Serotonin 1B Receptor Agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Serotonin 1B Receptor Agonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Satsuma Pharmaceuticals
• Pulmatrix
• Xoc Pharmaceuticals
• Contera Pharma

Key Products

• STS-101
• PUR-3100
• XC101
• JM-010

This product will be delivered within 2 business days.